XML 99 R68.htm IDEA: XBRL DOCUMENT v3.25.1
License, Acquisition, Research Collaboration and Sponsored Research Agreements - Additional Information (Details)
 1 Months Ended 3 Months Ended 12 Months Ended 37 Months Ended
Apr. 21, 2024
USD ($)
Apr. 19, 2024
USD ($)
Apr. 13, 2024
USD ($)
Dec. 03, 2021
USD ($)
IntegerItem
Oct. 04, 2021
USD ($)
Jul. 16, 2021
USD ($)
Jan. 25, 2021
USD ($)
Aug. 06, 2020
USD ($)
May 28, 2020
USD ($)
IntegerItem
Apr. 23, 2020
USD ($)
Nov. 30, 2020
USD ($)
shares
Dec. 31, 2024
USD ($)
Sep. 30, 2024
USD ($)
Mar. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2024
USD ($)
Nov. 07, 2023
shares
Dec. 31, 2022
shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Research and development expenses                               $ 74,091,000 $ 53,130,000      
Converted shares into common stock | shares                                     13,559,600 13,559,600
Stelios Therapeutics Inc                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Development milestone paid                               6,000,000        
Asset acquisition date of acquisition           Jul. 16, 2021                            
Asset acquisition percentage of outstanding stock acquisition           100.00%                            
Payment to selling shareholders                       $ 6,000,000                
Milestone Received                       $ 1,300,000       $ 1,300,000   $ 1,300,000    
Series A Convertible Preferred Stock                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Converted shares into common stock | shares                                     8,070,027 8,070,027
Maximum | Stelios Therapeutics Inc                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Payment to selling shareholders           $ 12,500,000                            
Adverum License Agreement | Adverum Biotechnologies Inc                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
One-time up-front non-refundable fee paid             $ 7,500,000             $ 7,500,000            
Development milestone paid                           $ 3,500,000            
Royalty payments description                               The Company is obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products (as defined in the Adverum Agreement).        
Research and development expenses                                 0      
License agreement termination notice period             120 days                          
Adverum License Agreement | Adverum Biotechnologies Inc | Maximum                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Development and regulatory milestones due             $ 17,500,000                          
Commercialization milestones due             $ 49,000,000                          
Cornell License Agreements | Cornell University                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Research and development expenses                               $ 700,000        
License agreement termination notice period                 90 days                      
Number of license agreements | IntegerItem                 2                      
Upfront payment in cash                 $ 300,000                      
Notes issued                 1,300,000                      
Notes with outstanding principal exchanged                     $ 1,300,000                  
Cornell License Agreements | Cornell University | Common Stock                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Converted shares into common stock | shares                                     126,258  
Cornell License Agreements | Cornell University | Series A Convertible Preferred Stock                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Shares issued on debt exchanged | shares                     1,337,610                  
Cornell First License Agreements | Cornell University | Maximum                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Specific clinical and regulatory milestones due                 8,400,000                      
Cornell Second License Agreements | Cornell University                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Clinical and regulatory milestone paid                             $ 100,000          
Cornell Second License Agreements | Cornell University | Maximum | Two Portfolios                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Specific clinical and regulatory milestones due                 4,300,000                      
Cornell Second License Agreements | Cornell University | Maximum | Third Portfolio                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Specific clinical and regulatory milestones due                 $ 600,000                      
Cornell Third License Agreements | Cornell University                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Research and development expenses                                 10,000      
License agreement termination notice period 90 days                                      
License fee and initial data transfer fee $ 600,000                                      
Annual data transfer fee 50,000                                      
Cornell Third License Agreements | Cornell University | Minimum                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Annual license maintenance fees 2,500                                      
Cornell Third License Agreements | Cornell University | Maximum                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Commercialization milestones due 100,000,000                                      
Annual license maintenance fees 25,000                                      
Regulatory milestone to be paid $ 2,100,000                                      
First UCSD License Agreement | Stelios Therapeutics Inc                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
One-time up-front non-refundable fee paid               $ 20,000   $ 20,000                    
License agreement termination notice period                   60 days                    
First UCSD License Agreement | Stelios Therapeutics Inc | Research and Development Expense                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
One-time up-front non-refundable fees                   $ 20,000                    
First UCSD License Agreement | Maximum | Stelios Therapeutics Inc                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Development and commercialization milestones due                   $ 4,800,000                    
Second UCSD License Agreement | Stelios Therapeutics Inc                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
License agreement termination notice period               60 days                        
Second UCSD License Agreement | Stelios Therapeutics Inc | Research and Development Expense                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
One-time up-front non-refundable fees               $ 20,000                        
Second UCSD License Agreement | Maximum | Stelios Therapeutics Inc                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Development and commercialization milestones due               $ 2,400,000                        
Third UCSD License Agreement                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Research and development expenses                               700,000        
Research agreements term     2 years                                  
Research agreement termination notice period     30 days                                  
Costs incurred for research     $ 700,000                                  
Payment to research and development                               $ 600,000        
Additional costs incurred for research     $ 600,000                                  
Third UCSD License Agreement | Stelios Therapeutics Inc                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
One-time up-front non-refundable fee paid         $ 20,000                              
License agreement termination notice period         60 days                              
Development and commercialization milestones description                               the Company to pay aggregate development and commercialization milestones of up to $4.0 million, and low- to mid-single digit royalties based on aggregate net sales.        
Third UCSD License Agreement | Stelios Therapeutics Inc | Research and Development Expense                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Development milestone paid                         $ 100,000              
One-time up-front non-refundable fees         $ 20,000                              
Third UCSD License Agreement | Maximum | Stelios Therapeutics Inc                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Development and commercialization milestones due         $ 4,000,000                              
UCSD Sponsored Research Agreements | Stelios Therapeutics Inc                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Research and development expenses                               $ 0 1,300,000      
Number of research agreements | IntegerItem       2                                
Research agreements term       2 years                                
Research agreement termination notice period       30 days                                
Costs incurred for research       $ 5,600,000                                
Payment to research and development                               700,000 400,000 $ 4,000,000    
Amended First UCSD Agreement                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Research and development expenses                               600,000        
Costs incurred for research   $ 700,000                                    
Payment to research and development                               300,000        
Research Collaboration Agreement | Weill Cornell Medical College                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Research and development expenses                               400,000 1,000,000      
Payment to research and development                               $ 300,000 $ 2,100,000